Human disease models

#Biotech #bit bio #Drug discovery #Human disease models

Bit.bio to develop human cell models for drug discovery 

Biotech company bit.bio has closed a $50 million Series C funding round to scale human cell models for drug discovery.  The company aims to use the funding to accelerate the development of, and access to, its products, scale its operations globally, expand into the multi-billion toxicology market, bolster its manufacturing operations and generate industry-leading… Read More

#Business & Investment #News

#AI / data analytics / healthtech / informatics #Alzheimer's #CNS #Gene editing #Human disease models #Interview #Neurodegenerative disorders #Neurology #Neuropsychiatric disorders #Neuroscience #Precision medicine #PrecisionLife #Stem cells

Podcast: Unlocking neuroscience drug discovery

This is the latest episode of the free DDW narrated podcast, titled “Innovative uses for biomarkers in drug discovery”, which covers three articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “Advances in neuroscience drug discovery”, “Putting human data at the centre of… Read More

#News

#CN Bio #Human disease models #Organ-on-a-chip #Partnership

CN Bio signs distributor agreement in South Korea

Organ-on-a-chip (OOC) company CN Bio has agreed a strategic partnership with SCINCO, a specialist scientific instrument company based in South Korea.   The agreement is designed to amplify the CN Bio’s presence in major Asian and Pacific markets and broaden access to its predictive human organ models.  CN Bio is establishing… Read More

#Business & Investment #News

#Amyotrophic lateral sclerosis (ALS) #App note #Human disease models #iPSC #Neuroscience

App Note: Human iPSC-derived disease models for ALS

Despite significant research and funding, the development of therapies for ALS has been challenging due to a lack of readily accessible human cell models, leading scientists to rely on animal models and cell lines that differ considerably from human biology. A new App Note is now available to download entitled… Read More

#News

#Amyotrophic lateral sclerosis (ALS) #Human disease models #iPSC #Neuroscience

Disease modelling with genetically matched iPSC-derived excitatory neurons

Download bit.bio’s application note to learn more about: Functional characterisation of human iPSC-derived ALS disease models using high throughput MEA. Phenotypic data showing reduced neuronal activity and network formation in ALS disease models. A genetically matched system in ioGlutamatergic Neurons that can be used to identify, measure and rescue disease-related… Read More

#Resources

#ADME / Tox #Human disease models #In vitro #iPSC #Toxicology #Webinar

Learn how to better replicate liver functionality for toxicology testing

A new event ‘Principles, pitfalls, and progress in modelling human liver toxicity and pharmacology in vitro’ is now open for registrations. The webinar, hosted by DDW and supported by bit.bio, will take place on 3 December 2024 at 4pm GMT. In his talk,… Read More

Webinar date:
Supported by bit.bio
#News

Human liver
#ADME / Tox #Human disease models #In vitro #iPSC #Toxicology #Webinar

Advancements in in vitro modelling for human liver toxicity

A new event ‘Principles, pitfalls, and progress in modelling human liver toxicity and pharmacology in vitro’ is now open for registrations. The webinar, hosted by DDW and supported by bit.bio, will take place on 3 December 2024 at 4pm GMT. In his talk,… Read More

Webinar date:
Supported by bit.bio
#News

Human liver
#ADME / Tox #Human disease models #In vitro #iPSC #Toxicology #Webinar

Register now: Discover human iPSC-derived hepatocytes for drug discovery

A new event ‘Principles, pitfalls, and progress in modelling human liver toxicity and pharmacology in vitro’ is now open for registrations. The webinar, hosted by DDW and supported by bit.bio, will take place on 3 December 2024 at 4pm GMT. In his talk,… Read More

Webinar date:
Supported by bit.bio
#News

#ADME / Tox #Human disease models #In vitro #iPSC #Toxicology #Webinar

Webinar: Overcome common pitfalls in in vitro modelling for liver toxicity

A new event ‘Principles, pitfalls, and progress in modelling human liver toxicity and pharmacology in vitro’ is now open for registrations. The webinar, hosted by DDW and supported by bit.bio, will take place on 3 December 2024 at 4pm GMT. In his talk,… Read More

Webinar date:
Supported by bit.bio
#News

#ADME / Tox #Human disease models #In vitro #iPSC #Toxicology

Principles, pitfalls, and progress in modelling human liver toxicity and pharmacology in vitro

In this webinar hosted by DDW and supported by bit.bio, Dr Stephen Ferguson, Investigator, Mechanistic Toxicology, Division of Translational Toxicology (DTT), National Institute of Environmental Health Sciences, explores the complexities of in vitro modelling for human liver toxicity and pharmacology. He discusses the development… Read More

Webinar date:
Supported by bit.bio
#Webinars

Organ-on-a-chip
#eBook #Human disease models #In vitro #Non-animal model (NAM) #Organ-on-a-chip

What are the benefits of organ-on-a-chip technology?

Organ-Chips have seen significant growth in adoption over the past few years. A blinded survey across industry and academia found: 97% of experienced Organ-Chip users say the technology is more predictive than conventional in vitro models. 70% of experienced Organ-Chip users describe the technology as more predictive than… Read More

#News

Emulate eBook
#Human disease models #In vitro #Non-animal model (NAM) #Organ-on-a-chip

Unlock Human-Relevant Insights with Organ-on-a-Chip Technology

Organ-Chips have seen significant growth in adoption over the past few years. A blinded survey across industry and academia found: 97% of experienced Organ-Chip users say the technology is more predictive than conventional in vitro models. 70% of experienced Organ-Chip users describe the technology as more predictive than… Read More

#Resources

Bone marrow organoids
#Drug discovery #Human disease models #Organoids #Preclinical development #Webinar

Are organoids superior to other preclinical models?

Developing new drugs is a complex and often lengthy process. A major roadblock lies in the limitations of traditional preclinical models, which often fail to accurately represent the intricate biology of human patients. Join DDW for a free event on 18 June, 3PM… Read More

Webinar date:
Supported by HUB Organoids
#News

Biological materials logistics
#Atelerix #Collaboration #DefiniGEN #Human disease models #Logistics #Sustainability

New approach preserves biological materials without freezing

DefiniGEN and Atelerix have reached an agreement which combines DefiniGEN’s iPSC hepatocytes (Opti-Heps) with Atelerix’s hydrogel preservation technology. The companies report that they have been able to successfully ship in vitro liver models from the UK to the US. In vitro liver models can speed… Read More

#News

Organoids
#Drug discovery #Human disease models #Organoids #Preclinical development #Webinar

Discover the latest innovations in organoid model development

Developing new drugs is a complex and often lengthy process. A major roadblock lies in the limitations of traditional preclinical models, which often fail to accurately represent the intricate biology of human patients. Join DDW for a free event on 18 June, 3PM… Read More

Webinar date:
Supported by HUB Organoids
#News

Organoids
#Drug discovery #Human disease models #Organoids #Preclinical development #Webinar

How are patient-derived organoids revolutionising drug discovery?

Developing new drugs is a complex and often lengthy process. A major roadblock lies in the limitations of traditional preclinical models, which often fail to accurately represent the intricate biology of human patients. Join DDW for a free event on 18 June, 3PM… Read More

Webinar date:
Supported by HUB Organoids
#News